Investors shouldn't have to think too hard about these great stocks.July is for barbecues, fireworks, and vacations. Many people don't want to think too hard about anything. Three Fool.com contributors think they have solutions for those investors who don't want to think too hard.Here's why they picked Eli Lilly (LLY 1.83%), Regeneron Pharmaceuticals (REGN 0.99%), and Vertex Pharmaceuticals (VRTX 0.91%) as no-brainer biotech stocks to buy in July.Eli Lilly is likely to surpass $1 trillion in valueDavid Jagi ...

Acquisition to expand Lilly's immunology pipeline with oral integrin therapies INDIANAPOLIS and WALTHAM, Mass., July 8, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Morphic Holding, Inc. (NASDAQ: MORF) today announced a definitive agreement for Lilly to acquire Morphic, a biopharmaceutical company developing oral integrin therapies for treatment of serious chronic diseases. Morphic's lead program is a selective oral small molecule inhibitor of α4β7 integrin for the treatment of inflammatory bo ...

Key TakeawaysNovo Nordisk and Eli Lilly shares lost ground Tuesday after U.S. President Joe Biden and Senator Bernie Sanders called out the companies in an op-ed for the cost of their medicines.Biden and Sanders said big pharmaceutical firms of charge "outrageous prices" for prescription drugs, and cited the cost of weight-loss drugs made by Novo Nordisk and Eli Lilly.Biden and Sanders warned they would take action if Novo Nordisk and other pharmaceutical companies do not “substantially lower" prescription ...

Forbes Community GuidelinesOur community is about connecting people through open and thoughtful conversations. We want our readers to share their views and exchange ideas and facts in a safe space.In order to do so, please follow the posting rules in our site's Terms of Service.  We've summarized some of those key rules below. Simply put, keep it civil.Your post will be rejected if we notice that it seems to contain:False or intentionally out-of-context or misleading informationSpamInsults, profanity, incoh ...

A sign with the company logo sits outside of the headquarters campus of Eli Lilly and Company on March 17, 2024 in Indianapolis, Indiana.The Food and Drug Administration on Tuesday approved Eli Lilly's Alzheimer's drug donanemab, expanding the limited treatment options for the mind-wasting disease in the U.S.The agency approved the treatment, which will be sold under the brand name Kisunla, for adults with early symptomatic Alzheimer's disease, according to the company.Nearly 7 million Americans have the co ...

Kisunla slowed cognitive and functional decline by up to 35% compared to placebo at 18 months in its pivotal Phase 3 study and reduced participants' risk of progressing to the next clinical stage of disease by up to 39% Kisunla is the first and only amyloid plaque-targeting therapy that used a limited-duration treatment regimen based on amyloid plaque removal; nearly half of study participants completed their course of treatment with Kisunla in 12 monthsOnce-monthly infusions of 30 minutes reduced amyloid p ...

Loading...Loading...Eli Lilly and Company LLY has hit a new 52-week high, climbing to $915.54 during Friday trading. The stock is up a remarkable 97.38% over the past year and 55.32% year-to-date, fueled by groundbreaking collaborations and bullish technical indicators.Eli Lilly’s Game-Changing Partnership With OpenAIEli Lilly announced a collaboration with Microsoft Corp-backed MSFT OpenAI to develop novel antimicrobials to combat drug-resistant pathogens. Diogo Rau, Lilly's executive vice president and ch ...

These stalwart companies could help you safely grow your wealth.There's something quite pleasant about having cash deposited into your investment account quarter after quarter and year after year. Here are two outstanding dividend stocks with long histories of rewarding their shareholders with steadily rising cash payments. Both stocks can help you build your own streams of passive income.Top dividend stock No. 1: Lockheed MartinLockheed Martin (LMT -0.01%) helps the U.S. government and its allies protect t ...

JHVEPhoto When I put a Buy rating on Eli Lilly (NYSE:LLY) a quarter ago, I didn’t believe that it was an investment for the short-term, but that it had potential from the longer term perspective. As it happens, it turned out to be one for short-term gains too, with an over 17% increase in price since I wrote. The stock is now up by 56% year-to-date [YTD], far outstripping the just 7% rise in the S&P 500 Health Care Index in this time. Price Chart (Source: Seeking Alpha) On the face of it, this is mind ...

A panel of advisors to the Food and Drug Administration (FDA) recently recommended Eli Lilly's Alzheimer's candidate.Pharmaceutical giant Eli Lilly (LLY -0.40%) is having a great year. Shares are up over 50% through the first half of the year on the heels of emerging blockbusters in the diabetes and obesity-care markets.While sales of Mounjaro and Zepbound are becoming increasingly scrutinized, I'd encourage investors to get up to speed on what else Lilly is working on. In early June, Lilly received some po ...